Please login to the form below

Not currently logged in
Email:
Password:

Orphan Drug

Sponsored by

Finalist

Vidaza

Celgene


Summary of work

Azacitidine (Vidaza), the first licensed treatment for the management of Intermediate-2 and high-risk Myelodysplastic Syndromes (MDS) across Europe, was seen by clinicians as a breakthrough treatment for patients with limited other options. However, prior to the positive NICE appraisal for Vidaza in February 2011, there was limited experience of prescribing of Vidaza outside the MDS centres of Excellence and larger teaching hospitals. Therefore, following the positive NICE recommendation, Celgene initiated a three-pronged customer support programme, focusing on clinicians, nurses and pharmacists based in District General Hospitals (DGH), to ensure all patients across England were able to access the treatment on the NHS. 

The support programme, based on critical insights from European markets where Vidaza was widely-used and existing prescribers and UK clinical trialists, focused on: 

  • Patient identification and diagnosis 
  • Initiation and maintaining patients on treatment 
  • Administration and side effect management. 

By the end of 2011, sales of Vidaza had trebled with 35 per cent of all eligible patients initiated on the treatment. In addition, the number of cycles of treatment per patient increased throughout the year – testament to the support programme Celgene had invested in.

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics